A new age of technology is upon us, dominated by recent advances in artificial intelligence and personalized treatments. Improving on our first-generation cancer treatment, Trojan Horse Liposome v2 will use these new developments to precisely and effectively eliminate malignant neoplasms and surpass THL v1's limitations. 

​

New Technologies

• AI-Powered Tissue Targeting via GPT Antigen Library Analysis

• Multi-Marker Targeting & AI-Powered Combination Therapy

• Controlled Release mechanism regulation

​

Improvements and new, critical discussions

• Biodegradability

• Bioethics and fair use of treatment

• Standardization of Production

• The future of THLv2

• Improving efficacy & accuracy of Apoptotic Factors

• Size optimizations

​

We expect to complete our research in 2025. Please use the button below to contact us with any questions, concerns, or ideas.